Tuesday, February 19, 2013

Shionogi and Intermune settle Lawsuit on Esbriet (Pirfenidone)

As per the settlement of the lawsuit, Shionogi will receive royalties from Intermune on sale of Esbriet (pirfenidone) in the Europe. Intermune will pay 4.25% of sales of Esbriet generated in European Union to Shionogi. The royalty will be payable for a period starting from January 2013 and completing on  Februrary 2021.  The royalty is payable to Shionogi because Intermune utilized Clinical data generated by Shionogi in its Market Authorization applciatio submitted to European union for approval of Esbriet. 


Enter your email address:


Delivered by FeedBurner